Cellomics announces the appointment of Dan Calvo, formerly of PerkinElmer Life Sciences as president and chief executive
Cellomics announces the appointment of Dan Calvo as president and CEO.
Calvo joins Cellomics from PerkinElmer Life Sciences, a $500 million global provider of instruments, reagents, software and services for the life sciences, drug discovery and diagnostics markets, where he was most recently VP, worldwide sales and service.
In that role, he led the integration and expansion of PerkinElmer's life science business, growing from $200 million to $500 million.
Calvo was previously senior VP, global sales and marketing for NEN Life Sciences, where he drove a significant turnaround of the company prior to the acquisition by PerkinElmer.
He spent more than 15 years at DuPont in various sales, marketing and operational assignments in their medical products business.
He received an AB degree in biochemistry from Princeton University, an MHS in environmental health engineering from Johns Hopkins University and an MBA in business administration from Bellarmine College.
He succeeds Lansing Taylor, who will remain as chairman of the board of directors.
